Genetics Study of In-stent Restenosis (ISR)
The investigators hypothesized that genetic variants of G protein influence the development of restenosis and clinical outcome of patients receiving drug-eluting stents (DES).
Coronary Artery Disease
|Study Design:||Observational Model: Case Control
Time Perspective: Retrospective
|Official Title:||G Protein β3 Subunit (GNB3) Polymorphism and Restenosis of Coronary Drug-eluting Stents|
- In-stent restenosis [ Time Frame: 6-24months after stent implanting ] [ Designated as safety issue: Yes ]
- target lesion revascularization (TLR) [ Time Frame: 6-24months after stent implanting ] [ Designated as safety issue: Yes ]
- re-myocardial infarction [ Time Frame: 6-24months after stent implating ] [ Designated as safety issue: Yes ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||March 2012|
|Estimated Study Completion Date:||September 2012|
|Estimated Primary Completion Date:||August 2012 (Final data collection date for primary outcome measure)|
Although drug-eluting stents (DES) have reduced restenosis rates compared with bare-metal stents, the restenosis rate is still high in the high-risk group. G protein plays important roles in the signal transduction leading to vascular smooth muscle proliferation. The initial and subsequent studies suggest that the T allele of C825T polymorphism is associated with enhanced transmembrane signaling via Gi proteins.
|Contact: Yamei Xufirstname.lastname@example.org|
|Contact: Yamei Xu 8613917133371 email@example.com|